ABOUT THIS SERIES —————————————————————————————————

Scenarios and strategies most relevant to <$200M medtech exit initiatives

The Exit Brief is built on the premise that the clients who benefit most from it already know the fundamentals. They don't need to be told what an LOI is. They need to understand why a particular earnout structure transfers risk in a specific direction, or when a warm strategic relationship becomes a liability rather than an asset.
Each piece addresses a concrete decision point, structural blind spot, or recurring failure mode, drawn from the lower middle market specifically, where comparable transaction data is scarce and the stakes for each individual decision are high.